Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe.

Simple item page
dc.contributor.affiliationInstituto of Pediatrics Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
dc.contributor.affiliationKilimanjaro Christian Medical Centre, Moshi, Tanzania.
dc.contributor.affiliationHarvard T.H. Chan School of Public Health, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
dc.contributor.affiliationCentre Aids Prevention Research South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
dc.contributor.affiliationDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, USA.
dc.contributor.affiliationUniversity of Zimbabwe College of Health Sciences, Paediatrics and Child Health, Harare, Zimbabwe. lstranix@uzchs-ctrc.org.
dc.contributor.affiliationCollege of Medicine - Johns Hopkins Research Project, Blantyre, Malawi.
dc.contributor.affiliationUniversity of North Carolina Project, Lilongwe, Malawi.
dc.contributor.affiliationUniversity of Zimbabwe College of Health Sciences - Clinical Trials Research Centre, 15 Phillips Avenue, Belgravia, Harare, Zimbabwe.
dc.contributor.affiliationDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
dc.contributor.affiliationPerinatal HIV Research Unit, Johannesburg, South Africa.
dc.contributor.affiliationDivision of Infectious Diseases, University of California Los Angeles, Los Angeles, USA.
dc.contributor.affiliationHarvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research in the Department of Biostatistics, Boston, USA.
dc.contributor.affiliationEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, USA.
dc.contributor.affiliationFaculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
dc.contributor.affiliationDepartment of Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa.
dc.contributor.affiliationFHI 360, IMPAACT Operations Center, Durham, NC, USA.
dc.contributor.affiliationUniversity of Zimbabwe College of Health Sciences - Clinical Trials Research Centre, 15 Phillips Avenue, Belgravia, Harare, Zimbabwe. lstranix@uzchs-ctrc.org.
dc.contributor.affiliationFrontier Science and Technology Research Foundation, Amherst, USA.
dc.contributor.affiliationDepartment of Infectious Diseases, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil.
dc.contributor.affiliationDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.
dc.contributor.affiliationResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, China.
dc.contributor.affiliationHospital Nossa Senhora da Conceicao, Porto Alegre, Brazil.
dc.contributor.affiliationLaboratorio de AIDS e Imunologia Molecular - Fiocruz, Hospital Geral de Nova Iguacu, Rio de Janeiro, Brazil.
dc.contributor.affiliationMakerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda.
dc.contributor.affiliationDepartment of Obstetrics and Gynaecology, BJ Government Medical College, Pune, India.
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorStranix-Chibanda L
dc.contributor.authorBrummel S
dc.contributor.authorPilotto J
dc.contributor.authorMutambanengwe M
dc.contributor.authorChanaiwa V
dc.contributor.authorMhembere T
dc.contributor.authorKamateeka M
dc.contributor.authorAizire J
dc.contributor.authorMasheto G
dc.contributor.authorChamanga R
dc.contributor.authorMaluwa M
dc.contributor.authorHanley S
dc.contributor.authorJoao E
dc.contributor.authorTheron G
dc.contributor.authorNevrekar N
dc.contributor.authorNyati M
dc.contributor.authorSantos B
dc.contributor.authorAurpibul L
dc.contributor.authorMubiana-Mbewe M
dc.contributor.authorOliveira R
dc.contributor.authorAnekthananon T
dc.contributor.authorMlay P
dc.contributor.authorAngelidou K
dc.contributor.authorTierney C
dc.contributor.authorZiemba L
dc.contributor.authorColetti A
dc.contributor.authorMcCarthy K
dc.contributor.authorBasar M
dc.contributor.authorChakhtoura N
dc.contributor.authorBrowning R
dc.contributor.authorCurrier J
dc.contributor.authorFowler MG
dc.contributor.authorFlynn P
dc.date.accessioned2025-05-23T11:41:19Z
dc.date.issued2019-Sep
dc.description.abstractThe PROMISE trial enrolled asymptomatic HIV-infected pregnant and postpartum women not eligible for antiretroviral treatment (ART) per local guidelines and randomly assigned proven antiretroviral strategies to assess relative efficacy for perinatal prevention plus maternal/infant safety and maternal health. The START study subsequently demonstrated clear benefit in initiating ART regardless of CD4 count. Active PROMISE participants were informed of results and women not receiving ART were strongly recommended to immediately initiate treatment to optimize their own health. We recorded their decision and the primary reason given for accepting or rejecting the universal ART offer after receiving the START information. One-third of participants did not initiate ART after the initial session, wanting more time to consider. Six sessions were required to attain 95% uptake. The slow uptake of universal ART highlights the need to prepare individuals and sensitize communities regarding the personal and population benefits of the "Treat All" strategy.
dc.identifier.doi10.1007/s10461-019-02624-3
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10452
dc.sourceAIDS and behavior
dc.titleSlow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe.

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
article.pdf
Size:
996.02 KB
Format:
Adobe Portable Document Format
Download

Collections

Published